Last reviewed · How we verify
Non-Q wave myocardial infarction — Treatment Landscape & Competitive Intelligence
4 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Aggrastat | TIROFIBAN | Medicure | Platelet Aggregation Inhibitor | Integrin alpha-IIb/beta-3 | 1998-01-01 | |
| Plavix | clopidogrel | Generic (originally Sanofi/BMS) | Thienopyridine antiplatelet agent | Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter | 1997-11-17 | |
| Heparin Sodium In Plastic Container | HEPARIN | Merck & Co. | Anti-coagulant | Antithrombin-III | 1939-01-01 | |
| Heparin Sodium In Plastic Container | Heparin Sodium | Fresenius Kabi | Anticoagulant | Antithrombin III, Coagulation Factors Xa and IIa | 1939-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Fresenius Kabi · 1 drug in Non-Q wave myocardial infarction
- Generic (originally Sanofi/BMS) · 1 drug in Non-Q wave myocardial infarction
- Medicure · 1 drug in Non-Q wave myocardial infarction
- Merck & Co. · 1 drug in Non-Q wave myocardial infarction
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Non-Q wave myocardial infarction:
- Non-Q wave myocardial infarction treatment updates — RSS
- Non-Q wave myocardial infarction treatment updates — Atom
- Non-Q wave myocardial infarction treatment updates — JSON
Cite this brief
Drug Landscape (2026). Non-Q wave myocardial infarction — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/non-q-wave-myocardial-infarction. Accessed 2026-06-11.
Related
- Non-Q wave myocardial infarction full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing